LEGN Legend Biotech Corporation

• CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $157 million
• EC and US FDA approved CARVYKTI® label expansion in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma
• Legend and Johnson & Johnson enter into Master Manufacturing and Supply Services Agreement with Novartis Pharmaceuticals Corporation
• On April 5, Legend Biotech earned a milestone payment of $45 million in connection with FDA’s approval of CARVYKTI’s label expansion to treat 2L+ MM, in accordance with the Janssen Agreement*
• Cash and cash equivalents, deposits, and short-term investments of $1.3 billion, as of March 31, 2024, which Legend believes will provide financial runway into 2026, when Legend Biotech anticipates achieving an operating profit

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2024 unaudited financial results and key corporate highlights.

“Legend made great progress in the first quarter, culminating in our exciting announcements in recent weeks. We received label expansions for CARVYKTI in the U.S., Europe, and Brazil that have changed the treatment paradigm for multiple myeloma and will enable more patients to receive our transformative therapy earlier in the course of their disease,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “With more patients needing access to CARVYKTI, we have increased our manufacturing capacity and have scaled up our operations to reach our goal of 10,000 annual doses by the end of 2025. The expansion of our partnership with Novartis demonstrates our commitment to ensuring every patient who needs CARVYKTI can access it.”

Regulatory Updates

• The U.S. Food and Drug Administration (FDA) approved CARVYKTI® for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and are refractory to lenalidomide following the Oncologic Drug Advisory Committee’s (ODAC) unanimous (11 to 0) vote recommending the approval of CARVYKTI®.
• The European Commission (EC) granted approval for the label expansion of CARVYKTI® for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide.
• The Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), approved CARVYKTI® for the treatment of adult patients with multiple myeloma, who previously received a proteasome inhibitor and are refractory to lenalidomide, as well as adult patients with relapsed or refractory multiple myeloma, who previously received a proteasome inhibitor, an immunomodulatory agent and anti-CD38 antibody.

Key Business Developments

• Legend and Johnson & Johnson* entered into a Master Manufacturing and Supply Services Agreement with Novartis Pharmaceuticals Corporation to supplement our existing manufacturing capabilities and increase commercial supply of CARVYKTI®
• Published inaugural Environmental, Social & Governance (ESG) report which aligns with the Sustainable Accounting Standards Board (SASB) Biotechnology and Pharmaceutical sector standards, shares ESG data collection and disclosure roadmap, and future growth strategy for good corporate citizenship

* In December 2017, Legend Biotech entered into an exclusive worldwide collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson company, to develop and commercialize cilta-cel (the Janssen Agreement).

First Quarter 2024 Financial Results

• License Revenue: License revenue was $12.2 million for the first quarter of 2024 and consisted of the recognition of deferred revenue in connection with the global license agreement with Novartis Pharma AG to develop, manufacture, and commercialize LB2102 and other potential CAR-T therapies selectively targeting DLL3. Legend did not recognize any license revenue for the first quarter of 2023.
• Collaboration Revenue: Collaboration revenue was $78.5 million for the first quarter of 2024 compared to $36.3 million for the first quarter of 2023. The increase was primarily due to an increase in revenue generated from sales of CARVYKTI® in connection with the Janssen Agreement.
• Collaboration Cost of Revenue: Collaboration cost of revenue was $49.1 million for the first quarter of 2024 compared to $35.6 million for the first quarter of 2023. The increase was primarily due to Legend Biotech’s share of the cost of sales in connection with CARVYKTI® sales under the Janssen Agreement.
• Cost of License and Other Revenue: Cost of license and other revenue for the three months ended March 31, 2024 was $5.6 million and consisted of costs in connection with the global license agreement with Novartis Pharma AG to develop, manufacture, and commercialize LB2102 and other potential CAR-T therapies selectively targeting DLL3. The Company did not incur any cost of license and other revenue for the three months ended March 31, 2023.
• Research and Development Expenses: Research and development expenses were $101.0 million for the first quarter of 2024 compared to $84.9 million for the first quarter of 2023. The increase was primarily driven by continuous research and development activities in cilta-cel, including start up costs for clinical production in Belgium and continued investment in Legend’s solid tumor programs.
• Administrative Expenses: Administrative expenses were $31.9 million for the first quarter of 2024 compared to $22.2 million for the first quarter of 2023. The increase was primarily due to the expansion of administrative functions and infrastructure to increase manufacturing capacity.
• Selling and Distribution Expenses: Selling and distribution expenses were $24.2 million for the first quarter of 2024 compared to $18.0 million for the first quarter of 2023. The increase was primarily driven by costs associated with commercial activities for cilta-cel, including the expansion of the sales force and second line indication launch preparation.
• Net Loss: Net loss was $59.8 million for the first quarter of 2024, compared to a net loss of $112.1 million for the first quarter of 2023.
• Cash Position: Cash and cash equivalents, time deposits, and short-term investments were $1.3 billion as of March 31, 2024.

Webcast/Conference Call Details: Legend Biotech will host its quarterly earnings call and webcast today at 8:00 am ET. To access the webcast, please visit this weblink.

A replay of the webcast will be available on Legend Biotech’s website at https://investors.legendbiotech.com/events-and-presentations.

About Legend Biotech Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at https://legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives; statements relating to CARVYKTI®, including Legend Biotech’s expectations for CARVYKTI® and its therapeutic potential; statements relating to the potential approval of CARVYKTI® for earlier lines of therapy; statements related to Legend Biotech manufacturing expectations for CARVYKTI®; and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 19, 2024. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

LEGEND BIOTECH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

   

 

 

Three Months Ended March 31,

 

 

2024

 

2023

US$’000, except share and per share data

 

(Unaudited)

 

(Unaudited)

REVENUE

 

 

 

 

License revenue

 

12,181

 

 

—

 

Collaboration revenue

 

78,481

 

 

36,280

 

Other revenue

 

3,329

 

 

56

 

Total revenue

 

93,991

 

 

36,336

 

Collaboration cost of revenue

 

(49,101

)

 

(35,613

)

Cost of license and other revenue

 

(5,638

)

 

—

 

Other income and gains

 

64,091

 

 

8,199

 

Research and development expenses

 

(100,964

)

 

(84,889

)

Administrative expenses

 

(31,929

)

 

(22,205

)

Selling and distribution expenses

 

(24,223

)

 

(17,954

)

Other expenses

 

(540

)

 

(10,734

)

Fair value gain of warrant liability

 

—

 

 

20,000

 

Finance costs

 

(5,475

)

 

(5,113

)

LOSS BEFORE TAX

 

(59,788

)

 

(111,973

)

Income tax expense

 

(5

)

 

(128

)

LOSS FOR THE PERIOD

 

(59,793

)

 

(112,101

)

Attributable to:

 

 

 

 

Ordinary equity holders of the parent

 

(59,793

)

 

(112,101

)

LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

 

 

 

 

Basic

 

(0.16

)

 

(0.34

)

Diluted

 

(0.16

)

 

(0.34

)

ORDINARY SHARES USED IN LOSS PER SHARE COMPUTATION

 

 

 

 

Basic

 

364,010,429

 

 

330,497,072

 

Diluted

 

364,010,429

 

 

330,497,072

 

LEGEND BIOTECH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

 

 

 

March 31, 2024

 

December 31, 2023

 

 

US$’000

 

US$’000

 

 

(Unaudited)

 

(Audited)

NON-CURRENT ASSETS

 

 

 

 

Property, plant and equipment

 

105,278

 

108,725

Advance payments for property, plant and equipment

 

563

 

451

Right-of-use assets

 

80,179

 

80,502

Time deposits

 

4,387

 

4,362

Intangible assets

 

3,152

 

4,061

Collaboration prepaid leases

 

166,344

 

151,216

Other non-current assets

 

1,412

 

1,493

Total non-current assets

 

361,315

 

350,810

CURRENT ASSETS

 

 

 

 

Collaboration inventories

 

22,146

 

19,433

Trade receivables

 

3,307

 

100,041

Prepayments, other receivables and other assets

 

85,603

 

69,251

Financial assets at fair value through profit or loss

 

150,449

 

663

Pledged deposits

 

359

 

357

Time deposits

 

254,357

 

30,341

Cash and cash equivalents

 

897,571

 

1,277,713

Total current assets

 

1,413,792

 

1,497,799

Total assets

 

1,775,107

 

1,848,609

CURRENT LIABILITIES

 

 

 

 

Trade payables

 

39,485

 

20,160

Other payables and accruals

 

136,012

 

132,802

Government grants

 

538

 

68

Lease liabilities

 

3,116

 

3,175

Tax payable

 

7,273

 

7,203

Contract liabilities

 

63,251

 

53,010

Total current liabilities

 

249,675

 

216,418

NON-CURRENT LIABILITIES

 

 

 

 

Collaboration interest-bearing advanced funding

 

286,396

 

281,328

Lease liabilities long term

 

45,174

 

44,169

Government grants

 

6,664

 

7,305

Contract liabilities

 

23,109

 

47,962

Other non-current liabilities

 

30

 

56

Total non-current liabilities

 

361,373

 

380,820

Total liabilities

 

611,048

 

597,238

EQUITY

 

 

 

 

Share capital

 

36

 

36

Reserves

 

1,164,023

 

1,251,335

Total ordinary shareholders’ equity

 

1,164,059

 

1,251,371

Total equity

 

1,164,059

 

1,251,371

Total liabilities and equity

 

1,775,107

 

1,848,609

LEGEND BIOTECH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

   

 

 

Three Months Ended March 31,

US$’000

 

2024

 

2023

 

 

 

(Unaudited)

 

 

(Unaudited)

 

 

 

 

 

LOSS BEFORE TAX

 

(59,788

)

 

(111,973

)

CASH FLOWS FROM/ (USED IN) OPERATING ACTIVITIES

 

15,518

 

 

(139,215

)

CASH FLOWS FROM/ (USED IN) INVESTING ACTIVITIES

 

(396,148

)

 

16,032

 

CASH FLOWS FROM/ (USED IN) FINANCING ACTIVITIES

 

831

 

 

(444

)

NET DECREASE IN CASH AND CASH EQUIVALENTS

 

(379,799

)

 

(123,627

)

Effect of foreign exchange rate changes, net

 

(343

)

 

(2,354

)

Cash and cash equivalents at beginning of the period

 

1,277,713

 

 

786,031

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS AT END OF THE YEAR

 

897,571

 

 

660,050

 

ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS

 

 

 

 

Cash and bank balances

 

1,156,674

 

 

670,065

 

Less: Pledged deposits

 

359

 

 

1,283

 

Time deposits

 

258,744

 

 

8,732

 

Cash and cash equivalents as stated in the statement of financial position

 

897,571

 

 

660,050

 

Cash and cash equivalents as stated in the statement of cash flows

 

897,571

 

 

660,050

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240513104697/en/

INVESTORS: Jessie Yeung (732) 956-8271 jessie.yeung@legendbiotech.com

PRESS: MaryAnn Ondish (914) 552-4625 media@legendbiotech.com